字号·· | 护眼
美国消费者新闻与商业频道

礼来达成一项减肥药以外的交易,另外,对英伟达再发谨慎提醒Eli Lilly makes a deal outside obesity. Plus, another word of caution on Nvidia

点「原文对照」整页切到原文,或双击某段只看那段的原文。

每个工作日,吉姆·克雷默的CNBC投资俱乐部都会发布《收盘冲刺》——一份可操作的午后更新,恰逢华尔街交易最后一小时。市场依然波动,因对AI基础设施主题持久性的疑虑而拖累华尔街。标普500指数下跌约1.8%,科技股为主的纳斯达克指数跌幅更大。AI交易面临压力,源于对英伟达未来作为更广泛AI建设财务后盾角色的不确定性,以及商务部采取行动堵住漏洞,该漏洞曾允许中国公司在其他国家远程租用英伟达的算力。

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. The market remains volatile as questions about the durability of the AI infrastructure theme weigh on Wall Street. The S & P 500 fell by about 1.8%, and the tech-heavy Nasdaq dropped even more. The AI trade came under pressure from uncertainty surrounding Nvidia's future role as a financial backstop for the broader AI buildout, as well as the Commerce Department's move to close a loophole that allowed Chinese companies to rent Nvidia's computing power in other countries remotely.

周一只有一个板块稳健上涨:消费必需品,其中包括俱乐部持仓股好市多、金佰利和星座品牌。投资者青睐必需品板块,因其增长虽慢但可靠,且拥有持续的分红和股票回购计划。过去几个月我们也采取了类似举措,卖出了科技股康宁和博通,并买入金佰利和星座品牌以进一步使投资组合远离AI交易实现多元化。必需品板块今年上涨20%,成为仅次于能源和医疗保健的年度第三大表现最佳板块。

Only one sector on Monday was solidly positive: consumer staples, which is home to Club stocks like Costco , Kimberly-Clark , and Constellation Brands . Investors have been gravitating toward the staples group for its slower but dependable growth and consistent dividend and share repurchase programs. We've made similar moves over the past few months, selling out of tech names like Corning and Broadcom, and adding Kimberly-Clark and Constellation to the portfolio to further diversify the portfolio away from the AI trade. The staples sector is up 20% this year, making it the third best-performing sector this year behind energy and healthcare.

信息技术板块周一下跌3%,将其年度涨幅推低至10%以下。让我们多花一点时间谈谈英伟达,因为周二晚间将发布财报。目前,我们更倾向于将该股视为“不予评级”,而非上周二下调至的相当于“持有”的2级评级。原因是,在黄仁勋辞去CEO职务后,公司面临巨大不确定性。

Information technology's 3% drop on Monday pushed the sector's gains this year below 10%. Let's spend a little more time on Nvidia, as we approach earnings Tuesday night. At the moment, we are considering the stock more of a "not rated" than the hold-equivalent 2 we downgraded it to last Tuesday. The reason why is that there is so much uncertainty at the company following Jensen Huang resignation as CEO.

我们仍不清楚的更大问题涉及公司继续为AI生态系统中的其他公司提供财务支持;管理层是否将坚持其对2028财年70%营收增长的预测;以及美国出口管制可能收紧至东南亚(除上述商务部决定之外)所带来的盈利风险。正是这些未知因素,促使Jim建议周四卖出部分股份以保全资本,他在周一早些时候重申了这一观点。

The larger questions we simply do not know the answer to relate to the company continuing to provide financial support to other companies in the AI ecosystem; whether management will stand by its 70% revenue growth forecast for fiscal year 2028; and the earnings risks associated with a potential tightening of U.S. export controls to Southeast Asia (beyond the aforementioned Commerce Department decision). These unknowns are why Jim recommended taking some shares off the table on Thursday as a matter of capital preservation, and he reiterated that view earlier Monday.

强生并非我们投资组合中周一达成交易的唯一制药公司。礼来同意收购Calytrix Bio,交易对价最高达15亿美元,Calytrix在一份新闻稿中宣布了这一消息。这家私营生物技术公司正在研发一种针对罕见血液疾病的早期抗体疗法。这是一笔规模较小的交易,短期内不会产生实质性影响,但此次收购符合礼来更广泛的并购策略,即利用其GLP-1类药物带来的暴利,将产品组合拓展至核心肥胖症业务之外。

Johnson & Johnson wasn't the only pharma company in our portfolio that struck a deal Monday. Eli Lilly has agreed to acquire to acquire Calytrix Bio for up to $1.5 billion, Calytrix announced in a press release. The privately held biotech is working on an early-stage antibody treatment for rare blood disorders. It's a small deal that doesn't move the needle any time soon, but the acquisition is fitting of Lilly's broader M & A strategy of using its GLP-1 windfall to expand its portfolio beyond its core obesity franchise.

礼来今年加快了交易步伐。据BiotechTV于10月7日发布的一篇采访报道,首席执行官David Ricks表示,礼来今年以来已完成40笔交易,超过2025年全年的总量。Ricks告诉该媒体:“去年礼来平均‘每两周’完成一笔交易。‘现在我们的速度是一周一笔。’”另外,巴克莱分析师周一将礼来的目标价从1400美元上调至1550美元。

Lilly has stepped up the pace of dealmaking this year. In a BiotechTV interview published Oct. 7, CEO David Ricks said Lilly had already done 40 deals year to date, more than all of 2025. Last year Lilly averaged one transaction "every two weeks," Ricks told the outlet. "Now we're doing like one a week."

此次上调主要源于分析师在礼来发布爆款第三季度财报后更新了模型。巴克莱指出,礼来定于12月7日举行的创新日将是一个契机,届时管理层可以阐述其在肥胖症领域之外的增长机遇。

Separately, analysts at Barclays raised their Lilly price target to $1,550 from $1,400 on Monday. The bump was mostly tied to the analysts updating their models after Lilly's blockbuster third-quarter earnings report .

Aecom将于周一收盘后发布财报。Home Depot、Disney、Viking Holdings、Klarna、Amer Sports和JD.com将于周二开盘前发布财报。在数据方面,我们将迎来10月零售销售报告。(请提供需要翻译的英文新闻文本。)

Barclays pointed to Lilly's upcoming innovation day on Dec. 7 as an opportunity where management can outline its growth opportunities beyond obesity. Aecom reports after the closing bell on Monday. Home Depot , Disney , Viking Holdings , Klarna , Amer Sports , and JD.com report before the opening bell on Tuesday. On the data side, we'll see the October retail sales report. ()

阅读媒体原文 ↗